Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer
C Dong, J Wu, Y Chen, J Nie, C Chen - Frontiers in pharmacology, 2021 - frontiersin.org
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
recurrence in most breast cancer patients, many patients exhibit acquired resistance …
Drug resistance in cancer: an overview
G Housman, S Byler, S Heerboth, K Lapinska… - Cancers, 2014 - mdpi.com
Cancers have the ability to develop resistance to traditional therapies, and the increasing
prevalence of these drug resistant cancers necessitates further research and treatment …
prevalence of these drug resistant cancers necessitates further research and treatment …
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Background Disease progression in patients with HER2-positive breast cancer receiving
trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular …
trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular …
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
TW Miller, BN Rexer, JT Garrett, CL Arteaga - Breast cancer research, 2011 - Springer
Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur
in> 70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway …
in> 70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway …
Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of
breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer …
breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer …
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
A Derakhshani, Z Rezaei, H Safarpour… - Journal of cellular …, 2020 - Wiley Online Library
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …
Therapeutic targeting of cancers with loss of PTEN function
LM Dillon, TW Miller - Current drug targets, 2014 - ingentaconnect.com
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is one of the most
frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN …
frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN …
PI3K mutations in breast cancer: prognostic and therapeutic implications
T Mukohara - Breast Cancer: Targets and Therapy, 2015 - Taylor & Francis
The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer.
Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (∼ 30%) …
Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (∼ 30%) …
Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer
J Baselga, GD Lewis Phillips, S Verma, J Ro… - Clinical cancer …, 2016 - AACR
Purpose: HER2-positive breast cancer is heterogeneous. Some tumors express mutations,
like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with …
like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with …
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A Gallardo, E Lerma, D Escuin, A Tibau… - British journal of …, 2012 - nature.com
Background: Trastuzumab resistance hampers its well-known efficacy to control HER2-
positive breast cancer. The involvement of PI3K/Akt pathway in this mechanism is still not …
positive breast cancer. The involvement of PI3K/Akt pathway in this mechanism is still not …